Yahoo Finance • 17 hours ago
NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2025 financial results on Wednesday, November 5, 2025 before the U.S. financial markets open. The company... Full story
Yahoo Finance • 8 days ago
Revolution Medicines, Inc. (NASDAQ:RVMD) is among the most promising biotech stocks to buy according to hedge funds. On September 24, 2025, General Counsel and Officer of Revolution Medicines, Inc. (NASDAQ:RVMD), Jeff Cislini, offloaded 1,... Full story
Yahoo Finance • 11 days ago
NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independen... Full story
Yahoo Finance • 18 days ago
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story
Yahoo Finance • 21 days ago
NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at Bernstein’s 2nd Annual Healthcare Forum on Tuesday, September 23, 2025 at 2:50 p.m. ET. The we... Full story
Yahoo Finance • 24 days ago
In this article, we will be taking a look at the 12 Cheap Healthcare Stocks to Buy Now. Royalty Pharma plc is one of them. Royalty Pharma plc (NASDAQ:RPRX), a biopharmaceutical company specializing in acquiring and managing royalties from... Full story
Yahoo Finance • 29 days ago
In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. Royalty Pharma plc is one of them. Royalty Pharma plc (NASDAQ:RPRX) tops our list for being one of the best performing stocks. It is a lead... Full story
Yahoo Finance • 29 days ago
Royalty Pharma plc On track to deliver Portfolio Receipts of $4.7 billion or more by 2030, significantly ahead of consensus Goal to achieve at least mid-teens average annual total shareholder return over next 5 years with significant upsi... Full story
Yahoo Finance • 30 days ago
First of its kind report offers insight from over 110 biopharma executives into the benefits of royalties, current market dynamics and outlook for royalty market expansionRoyalties have become integral to biopharma’s diversified capital la... Full story
Yahoo Finance • last month
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025 at 3:... Full story
Yahoo Finance • last month
(RTTNews) - Royalty Pharma plc (RPRX) announced the pricing of a $2.0 billion offering of senior unsecured notes. The issuance includes $600 million of 4.450% Notes due 2031, $900 million of 5.200% Notes due 2035, and $500 million of 5.950... Full story
Yahoo Finance • last month
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $2.0 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”): $600 millio... Full story
Yahoo Finance • last month
* Zenas BioPharma (NASDAQ:ZBIO [https://seekingalpha.com/symbol/ZBIO]), and Royalty Pharma (RPRX [https://seekingalpha.com/symbol/RPRX]) announced [https://seekingalpha.com/pr/20217104-zenas-biopharma-and-royalty-pharma-enter-into-obexel... Full story
Yahoo Finance • last month
Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related DiseaseAdditional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval fo... Full story
Yahoo Finance • last month
- Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease - - Additional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA app... Full story
Yahoo Finance • last month
Royalty Pharma announced it has acquired a royalty interest in Amgen’s Imdelltra from BeOne Medicines for US$885 million upfront, with an option to purchase up to an additional US$65 million in royalties over the next 12 months. This trans... Full story
Yahoo Finance • 2 months ago
(Reuters) -Royalty Pharma said on Monday it has signed a deal with BeOne Medicines to acquire a royalty interest in Amgen’s drug for small cell lung cancer for up to $950 million. The deal gives Royalty Pharma access to roughly 7% of glob... Full story
Yahoo Finance • 2 months ago
BeOne Medicines (NASDAQ:ONC [https://seekingalpha.com/symbol/ONC]) is selling its royalty rights on the worldwide sales, excluding China, of Amgen’s (NASDAQ:AMGN [https://seekingalpha.com/symbol/AMGN]) cancer drug Imdelltra (tarlatamab-dll... Full story
Yahoo Finance • 2 months ago
Imdelltra is a first-in-class immunotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC) marketed by AmgenRoyalty Pharma to pay $885 million upfront; BeOne Medicines to retain a $65 million option to sell additiona... Full story
Yahoo Finance • 2 months ago
Technical breakout strategies focus on finding stocks with solid momentum that are pausing before their next upward move. By using a high ChartMill Technical Rating (which measures trend strength) along with a high Setup Quality Rating (wh... Full story